Zonisamide for migraine prophylaxis in Patients refractory to topiramate

Clinical Neuropharmacology

Volumn 32, Issue 2, 2009, Pages 103-106

  Bermejo, Pedro Emilio ^b   Dorado, Rodolfo ^a  

^a Ruber International Hospital   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Anticonvulsants; Calcium channel; Migraine; Prophylaxis; Topiramate; Zonisamide

Indexed keywords

ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL T TYPE; NONSTEROID ANTIINFLAMMATORY AGENT; TOPIRAMATE; TRIPTAN DERIVATIVE; ZONISAMIDE;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONCENTRATION LOSS; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPHORIA; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PAIN ASSESSMENT; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; VISUAL ANALOG SCALE;

ADULT; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRUCTOSE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67749139883     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318170577f     Document Type: Article

References (43)

1. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-495.
2. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-973.
3. Diener H-C, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-950.
4. Dib JG. Focus on topiramate in neuropathic pain. Curr Med Res Opin 2004;20(12):1857-1861.
5. Bermejo PE, Dorado R. Topiramato en el temblor esencial refractario. Rev Neurol 2007;45(3):188-189.
6. Arnone D. Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 2005;4(1):5.
7. Angehagen M, Ben-Menachem E, Ronnback L, et al. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res 2003;28(2):333-340.
8. Limmroth V, Biondi D, Pfeil J, et al. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 2007;47(1):13-21.
9. Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007;75:75-83.
10. Frampton JE, Scott LJ. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005;19:347-367.
11. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987;413:185-188.
12. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007;30:230-240.
13. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996;5:115-119.
14. Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf 2007;6(5):547-557.
15. Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin 2007;23(8):1765-1773.
16. Romigi A, Izzi F, Placidi F, et al. Topiramate-induced restless legs syndrome: a report of two cases. J Neurol 2007;254(8):1120-1121.
17. Bermejo PE, Zabala JA, Saez R. Restless legs syndrome induced by zonisamide. Mov Disord 2007;22(10):1517-1518.
18. Ettinger AB, Argoff CE. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 2007;4(1):75-83.
19. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003;25:2506-2538.
20. Bermejo Velasco PE, Velasco Calvo R. Nuevos fármacos antiepilépticos en la profilaxis de la migraña. Med Clin (Barc) 2007;128:379-382.
21. Drake ME, Greathouse NI, Renner JB, et al. Open-label zonisamide for refractory migraine. Clin Neuropharmacol 2004;27:278-280.
22. Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache 2006;46:804-807.
23. Ashkenazi A, Benlifer A, Korenblit J, et al. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia 2006;26:1199-1202.
24. Headache Classification Committee. The International Classification of Headache Disorders. 2nd ed. Cephalalgia 2004;24:1-160.
25. Mulleners WM, Whitmarsch TE, Steiner TJ. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia 1998;18:52-56.
26. Krusz JC. Zonisamide in the treatment of headache disorders [abstract]. Cephalalgia 2001;21:374-375.
27. Bernstein CD, Diaz JH, Gould HJ. A possible role for zonisamide in treating neuropathic pain: a case of idiopathic polyneuropathy. Pain Pract 2002;2:134-136.
28. Ghaemi SN, Zablotsky B, Filkowski MM, et al. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol 2006;26:385-388.
29. Zesiewicz TA, Ward CL, Hauser RA, et al. A double-blind placebo-controlled trial of zonisamide (Zonegran) in the treatment of essential tremor. Mov Disord 2007;22:279-282.
30. Morgan JC, Sethi KD. Zonisamide in Parkinson's disease. Curr Neurol Neurosci Rep 2007;7:275-277.
31. Bermejo PE. Zonisamide in patients with essential tremor and Parkinson's disease. Mov Disord 2007;22(4):2137-2138.
32. Wang PW, Yang YS, Chandler RA, et al. Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. J Psychiatr Res. 2007. In press.
33. Kinrys G, Vasconcelos e Sa D, Nery F. Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract 2007;61:1050-1053.
34. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006;67:1897-1906.
35. Farmer K, Cady R, Bleiberg J, et al. Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study. Headache 2001;41:377-384.
36. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large, controlled trial. Arch Neurol 2004;61:490-495.
37. Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med 2008;9:175-185.
38. Diener HC, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-950.
39. Bermejo Velasco PE, Velasco Calvo R. Nuevos fármacos antiepilépticos y dolor neuropático. De la medicina molecular a la clínica. Med Clin (Barc) 2007;129:542-550.
40. Bermejo Velasco PE. Tratamiento del temblor esencial. Med Clin (Barc) 2007;129:222-227.
41. Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13:5-9.
42. Lory P, Chemin J. Towards the discovery of novel T-type calcium channel blockers. Expert Opin Ther Targets 2007;11:717-722.
43. Eggers AE. A chronic dysfunctional stress response can cause stroke by stimulating platelet activation, migraine, and hypertension. Med Hypotheses 2005;65:542-545.